SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

被引：5
|
作者：
Sutherland, May S. K. [1 ]
Walter, Roland B. [2 ]
Jeffrey, Scott C. [1 ]
Burke, Patrick J. [1 ]
Yu, Changpu [1 ]
Harrington, Kimberly H. [2 ]
Stone, Ivan [1 ]
Ryan, Maureen C. [1 ]
Sussman, Django [1 ]
Zeng, Weiping [1 ]
Benjamin, Dennis R. [1 ]
Bernstein, Irwin D. [2 ]
Senter, Peter D. [1 ]
Drachman, Jonathan G. [1 ]
McEarchern, Julie A. [1 ]
机构：
[1] Seattle Genet Inc, Res & Translat Med, Bothell, WA USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3589.3589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3589
引用
收藏
页数：2
相关论文
共 45 条
  • [31] IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells
    Krystal, Watkins M.
    Walker, Russell
    Fishkin, Nathan
    Audette, Charlene
    Kovtun, Yelena
    Romanelli, Angela
    BLOOD, 2015, 126 (23)
  • [32] IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS
    Kovtun, Y.
    Jones, G.
    Harvey, L.
    Rui, L.
    Audette, C.
    Liu, F.
    Bai, C.
    Wilhelm, A.
    Yoder, N. C.
    Adams, S.
    Goldmacher, V. S.
    Chari, R.
    Chittenden, T.
    HAEMATOLOGICA, 2016, 101 : 222 - 222
  • [33] BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Jagannath, Sundar
    Chanan-Khan, Asher
    Heffner, Leonard T.
    Avigan, David
    Zimmerman, Todd M.
    Lonial, Sagar
    Lutz, Robert J.
    Engling, Andre
    Uherek, Christoph
    Osterroth, Frank
    Ruehle, Markus
    Beelitz, Michelle A.
    Niemann, Gabriele
    Wartenberg-Demand, Andrea
    Haeder, Thomas
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    BLOOD, 2011, 118 (21) : 142 - 143
  • [34] The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
    Beckwith, K. A.
    Frissora, F. W.
    Stefanovski, M. R.
    Towns, W. H.
    Cheney, C.
    Mo, X.
    Deckert, J.
    Croce, C. M.
    Flynn, J. M.
    Andritsos, L. A.
    Jones, J. A.
    Maddocks, K. J.
    Lozanski, G.
    Byrd, J. C.
    Muthusamy, N.
    LEUKEMIA, 2014, 28 (07) : 1501 - 1510
  • [35] PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma
    Wang, Lei
    Liu, Haidong
    Shang, Xiao
    Han, Tae
    Zhao, Baiteng
    CANCER RESEARCH, 2022, 82 (12)
  • [36] Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
    Abrams, Tinya
    Connor, Anu
    Fanton, Christie
    Cohen, Steven B.
    Huber, Thomas
    Miller, Kathy
    Hong, E. Erica
    Niu, Xiaohong
    Kline, Janine
    Ison-Dugenny, Marjorie
    Harris, Sarah
    Walker, Dana
    Krauser, Klaus
    Galimi, Francesco
    Wang, Zhen
    Ghoddusi, Majid
    Mansfield, Keith
    Lee-Hoeflich, Si Tuen
    Holash, Jocelyn
    Pryer, Nancy
    Kluwe, William
    Ettenberg, Seth A.
    Sellers, William R.
    Lees, Emma
    Kwon, Paul
    Abraham, Judith A.
    Schleyer, Siew C.
    CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4297 - 4308
  • [37] ROBUST ANTITUMOR ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE SGN-35 WHEN ADMINISTERED EVERY 3 WEEKS TO PATIENTS WITH RELAPSED OR REFRACTORY CD30 POSITIVE HEMATOLOGIC MALIGNANCIES IN A PHASE 1 STUDY
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Kennedy, D. A.
    Sievers, E. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 205 - 205
  • [38] Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
    Gerber, Hans-Peter
    Kung-Sutherland, May
    Stone, Ivan
    Morris-Tilden, Carol
    Miyamoto, Jamie
    McCormick, Renee
    Alley, Stephen C.
    Okeley, Nicole
    Hayes, Brad
    Hernandez-Ilizaliturri, Francisco J.
    McDonagh, Charlotte F.
    Carter, Paul J.
    Benjamin, Dennis
    Grewal, Iqbal S.
    BLOOD, 2009, 113 (18) : 4352 - 4361
  • [39] BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Jagannath, Sundar
    Chanan-Khan, Asher A.
    Heffner, Leonard T.
    Avigan, David
    Lutz, Robert J.
    Uherek, Christoph
    Osterroth, Frank
    Ruehle, Markus
    Haeder, Thomas
    Niemann, Gabriele
    Wartenberg-Demand, Andrea
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1262 - 1262
  • [40] BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity
    Heffner, Leonard T.
    Jagannath, Sundar
    Zimmerman, Todd M.
    Lee, Kelvin P.
    Rosenblatt, Jacalyn
    Lonial, Sagar
    Lutz, Robert J.
    Czeloth, Niklas
    Osterroth, Frank
    Ruehle, Markus
    Beelitz, Michelle A.
    Wartenberg-Demand, Andrea
    Haeder, Thomas
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    BLOOD, 2012, 120 (21)
12345